TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03083561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT01105806

Intervention type: BEHAVIORAL
Intervention: cardiopulmonary resuscitation (CPR) narrative script and questionnaires
Description: Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
Study: NCT02063100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets
Description: Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50mg
Description: Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets and Losartan potassium 50mg
Description: Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets and Losartan potassium 100mg
Description: Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100mg
Description: Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
Study: NCT02692690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulette r4x
Study: NCT03083561

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02926729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nonlinear microscopy imaging of excised surgical margins
Description: Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
Study: NCT02994602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone + Testosterone Combination Gel
Description: The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
Study: NCT02401373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-EBOV
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-EBOV
Description: intramuscular injection
Study: NCT02753205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: infusion of normal saline
Study: NCT00575497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Six Day per week short daily hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Six nights per week nocturnal hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Every other day short daily hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Every other night hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: 5 days per week short daily hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: 5 nights per week hemodialysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hemodialysis
Description: 3 days per week short daily hemodialysis
Study: NCT02152228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EnteraBio's Oral Parathyroid Hormone (1-34)
Description: Oral administration
Study: NCT02795208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver
Description: The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
Study: NCT03942679

Intervention type: OTHER
Group type: OTHER
Intervention: PRP
Description: Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
Study: NCT02035332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation System
Description: Ablation of the endometrial lining of the uterus using the Aurora System
Study: NCT01272960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-Placenta Mirena Insertion
Description: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
Study: NCT02926729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard lumpectomy without nonlinear microscopy imaging
Description: Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
Study: NCT03290456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5mg/day extended of 12 additional months
Description: Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
Study: NCT01272960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interval Insertion
Description: Insertion of Mirena 4-8 weeks post partum after vaginal delivery
Study: NCT03463915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bladder instillation WITH triamcinolone acetonide
Description: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bladder instillation WITHOUT triamcinolone acetonide
Description: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
Study: NCT04845464

Intervention type: OTHER
Intervention: Cognitive Assessment (not diagnostic)
Description: Sleep quality and cognition will be assessed in young adults
Study: NCT02225379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-Sense (non invasive sensor)
Description: Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
Study: NCT04319601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: a new chemotherapy regimen
Study: NCT00297115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg, once daily, oral administration in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT02276066

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GFR by Iohexol
Description: Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GFR by Iohexol
Description: Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Collection
Description: Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine Collection
Description: Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
Study: NCT02393521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shindo® vibration mattress
Description: vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
Study: NCT02571322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperVibe Whole Body Vibration training device
Description: Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
Study: NCT01313546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of quariceps muscle
Description: stimulation of quadriceps muscle through the stimulating catheter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of quariceps muscle
Description: stimulation of quadriceps muscle through the stimulating catheter
Study: NCT03185832

Intervention type: DEVICE
Intervention: CRT-D
Description: This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities

Intervention type: DEVICE
Intervention: ICD
Description: This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities

Intervention type: DEVICE
Intervention: PM / CRT-P
Description: This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities

Intervention type: OTHER
Intervention: Non-device
Description: Patient enrolled but not implanted with a Defibrillator or Pacemaker
Study: NCT03133104

Intervention type: OTHER
Intervention: Antenatal corticosteroids
Description: Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
Study: NCT00369681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT03290456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5mg/day extended of 12 additionnal months.
Description: 1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
Study: NCT02263391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in or Opt-out testing
Description: Study participants will be offered a health screening onsite.
Study: NCT00369681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study: NCT03675451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89ZR-DF-IAB2M
Description: injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC
Description: Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
Study: NCT03906305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept
Description: Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept
Description: Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)
Study: NCT01401413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: 8 mg nightly for 30 nights
Study: NCT02263391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in or Opt-out testing
Description: Study participants will be offered a health screening onsite.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Study participants will be invited to participate in a focus group discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Study participants will be invited to participate in a focus group discussion.
Study: NCT02586610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Days 1, 22 and 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
Study: NCT02683278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral
Description: Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-acceptance
Description: Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
Study: NCT00536627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine pCMVS2.S
Description: Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
Study: NCT01665222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets
Study: NCT01401413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control i pill nightly for 30 nights
Study: NCT02964455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: continuous chest radiation at 64 Gy/32f
Study: NCT04581148

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
Study: NCT04422613

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pulmonary anomalies 4 months after documented COVID-19 pneumonia
Description: Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
Study: NCT01665222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets
Study: NCT02791321

Intervention type: OTHER
Group type: OTHER
Intervention: ADS severity
Description: Evaluation of the ADS severity with the CARS scale

Intervention type: OTHER
Group type: OTHER
Intervention: Adaptative and intellectual functioning
Description: Evaluation with IQ and Vineland II scale

Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatric and somatic comorbidities
Description: Evaluation with the Reiss, DSQIID and CIRS Scales
Study: NCT02327403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.